Rituxan Sample Coding
This coding information may assist you as you complete the payer forms for Rituxan. These tables are provided for informational purposes only. Please visit CMS.gov or other payers’ websites to obtain additional guidance on their processes related to billing and coding for single-use vials and wastage.
You can generate a PDF of these coding tables by selecting either the "Download All" or the "Download Section" button:
- "Download All" lets you download or print a coding table for all indications
- "Download Section" lets you download or print a coding table for a specific indication
Effective January 1, 2019, the new J-code for Rituxan will be J9312.
Rheumatoid Arthritis (RA)
|Diagnosis: ICD-10-CM||M05.60—M05.69||Rheumatoid arthritis with involvement of other organs and systems|
|M05.70—M05.79||Rheumatoid arthritis with rheumatoid factor without organ or systems involvement|
|M06.00—M06.09||Rheumatoid arthritis without rheumatoid factor|
|M06.9||Rheumatoid arthritis, unspecified|
|Drug: HCPCS||J9310 (valid through December 31, 2018)||Injection, rituximab, 100 mg|
|J9312 (effective January 1, 2019)||Injection, rituximab, 10 mg|
|Other drugs: for ancillary premedications and supplies as appropriate||J1100||Injection, dexamethasone sodium phosphate, 1 mg|
|J1200||Injection, diphenhydramine HCL, up to 50 mg|
|J2920||Injection, methylprednisolone sodium succinate, up to 40 mg|
|J2930||Injection, methylprednisolone sodium succinate, up to 125 mg|
|J7030||Infusion, normal saline solution, 1000 cc|
|J7040||Infusion, normal saline solution, sterile (500 mL = 1 unit)|
|J7050||Infusion, normal saline solution, 250 cc|
|Drug: NDC |
Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.
|50242-051-21||50242-0051-21||100 mg/10 mL single-use vial|
|50242-053-06||50242-0053-06||500 mg/50 mL single-use vial|
|Administration procedures: CPT||96413||Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug|
|96415||Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)|
|96367||Intravenous infusion, for therapy,
prophylaxis or diagnosis (specify substance or drug); additional
sequential infusion, up to 1 hour (List separately in addition
to code for primary procedure) |
(Report 96367 in conjunction with 96365, 96374, 96409, 96413 if provided as a secondary or subsequent service after a different initial service is administered through the same IV access. Report 96367 only once per sequential infusion of same infusate mix)
|96375||Intravenous infusion, for therapy,
prophylaxis or diagnosis (specify substance or drug); each
additional sequential intravenous push of a new substance/drug
(List separately in addition to code for primary
(Use 96375 in conjunction with 96365, 96374, 96409, 96413)
(Report 96375 to identify intravenous push of a new substance/drug if provided as a secondary or subsequent service after a different initial service is administered through the same IV access)
CPT=Current Procedural Terminology.
HCPCS=Healthcare Common Procedure Coding System.
ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification.
NDC=National Drug Code.
These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Biogen do not make any representation or guarantee concerning reimbursement or coverage for any service or item.
Many payers will not accept unspecified codes. If you use an
unspecified code, please check with your payer.
If your patient’s health insurance plan has issued a denial, your Immunology Field Reimbursement Manager (IFRM) or Genentech Rheumatology Access Solutions Specialist can provide resources as you prepare an appeal submission, as per your patient’s plan requirements.
If a plan issues a denial:
- The denial should be reviewed, along with the health insurance
plan’s guidelines to determine what to include in your patient’s
- Your IFRM or Genentech Rheumatology Access Solutions Specialist has local payer coverage expertise and can help you determine specific requirements for your patient.
A sample appeal letter and additional considerations are available in Forms and Documents.
Appeals cannot be completed or submitted by Genentech Rheumatology Access Solutions on your behalf.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
- Rituxan® (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapies
- Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
- Rituxan® (rituximab) is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris
BOXED WARNINGS and Additional Important Safety Information
Infusion-Related Reactions: Rituxan administration can result in serious, including fatal infusion-related reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions.
Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan.
Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation.
Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan.
Warnings and Precautions
Rituxan administration can also result in additional serious, including fatal, adverse reactions including:
- Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function
- Infections: Withhold Rituxan and institute appropriate anti-infective therapy. Rituxan is not recommended for use in patients with severe, active infections
- Cardiovascular adverse reactions: Discontinue infusions in case of serious or life-threatening events
- Renal toxicity: Discontinue in patients with rising serum creatinine or oliguria
- Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms
- Immunizations: Live virus vaccinations prior to or during Rituxan treatment are not recommended
- Embryo-Fetal toxicity: Can cause neonatal harm. Advise of potential risk to neonates and use of effective contraception
- Patients with RA should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
- The use of Rituxan in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended
- Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA, MPA, or PV patients exhibiting peripheral B-cell depletion following treatment with Rituxan
Most Common Adverse Reactions
Rheumatoid Arthritis (RA)
Most common adverse reactions (≥10%) were upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis. Other important adverse reactions include infusion-related reactions, serious infections, and cardiovascular events.
Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
Most common adverse reactions (≥15%) were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion-related reactions.
Pemphigus Vulgaris (PV)
Most common adverse reactions (≥15%) were infusion-related reactions and depression. Other important adverse reactions include infections.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional Important Safety Information, please see the Rituxan full Prescribing Information, including BOXED WARNINGS.